ABIONYX Successfully Completes €3.4 Million Capital Increase

ABIONYX Pharma has conducted a successful capital increase, raising approximately €3.4 million. This increase was achieved through the issue of 2,472,000 new shares, each accompanied by a warrant. The subscription price was set at €1.37 per share with a warrant.

Each warrant allows the holder to subscribe for a new share at a price of €3, with an exercise period of three years. This fundraising aims to bolster the company's cash position and support its development efforts, particularly in sepsis and the U.S. market.

The shares issued will constitute about 7.62% of the current share capital. These shares carry dividend rights and are assimilated to existing shares, trading on Euronext. The operation, authorized by the Board of Directors, does not require an AMF-approved prospectus.